Breast Surgical Unit, Breast Cancer Center, Department of Gynecology, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Eur J Surg Oncol. 2013 Jul;39(7):766-73. doi: 10.1016/j.ejso.2013.03.011. Epub 2013 Apr 19.
The one-step nucleic acid amplification (OSNA) is a molecular procedure that yields a semiquantitative result for detection of nodal metastasis. Size of metastasis in the sentinel lymph node (SLN) by conventional histology has been described as a predictive factor for additional axillary metastasis. The objective of this study is to quantify intraoperatively the total tumoral load (TTL) in the positive SLNs assessed by OSNA and to determine whether this TTL predicts non-SLN metastasis in patients with clinically node negative early stage breast cancer.
306 patients with cT1-3N0 invasive breast cancer who had undergone intraoperative SLN evaluation by OSNA were included. TTL was defined as the addition of CK19 mRNA copies of each positive SLN (copies/μL).
TTL was a predictive factor of additional non-SLN metastasis in the complete axillary lymph node dissection (cALND) (OR, 1.67; 95% CI, 1.18-2.35). In the multivariate analysis, the TTL was a predictor of non-SLN metastasis in HR positive patients (OR, 1.69; 95% CI, 1.19-2.41). In our cohort of patients, with a TTL ≤1.2 × 10(5) copies/μL, there was a specificity of 85.3% and negative predictive value (NPV) of 80%. If we consider only the HR positive patients, with a TTL ≤5 × 10(5) copies/μL there was a specificity of 86.7% and NPV of 83.7%.
TTL assessed by OSNA assay predicts for additional non-SLN metastasis and this intraoperative tool can help guiding decisions on performing a cALND in breast cancer patients.
一步法核酸扩增(OSNA)是一种分子程序,可对淋巴结转移进行半定量检测。传统组织学检测到的前哨淋巴结(SLN)中的转移灶大小已被描述为预测腋窝淋巴结进一步转移的因素。本研究的目的是通过 OSNA 术中定量评估阳性 SLN 中的总肿瘤负荷(TTL),并确定在临床淋巴结阴性早期乳腺癌患者中,该 TTL 是否预测非 SLN 转移。
共纳入 306 例接受 OSNA 术中 SLN 评估的 cT1-3N0 浸润性乳腺癌患者。TTL 定义为每个阳性 SLN 的 CK19 mRNA 拷贝数之和(拷贝/μL)。
TTL 是完整腋窝淋巴结清扫术(cALND)中额外非 SLN 转移的预测因素(OR,1.67;95%CI,1.18-2.35)。在多变量分析中,TTL 是 HR 阳性患者非 SLN 转移的预测因素(OR,1.69;95%CI,1.19-2.41)。在我们的患者队列中,TTL ≤1.2×10(5)拷贝/μL 时,特异性为 85.3%,阴性预测值(NPV)为 80%。如果我们仅考虑 HR 阳性患者,TTL ≤5×10(5)拷贝/μL 时,特异性为 86.7%,NPV 为 83.7%。
OSNA 检测的 TTL 可预测额外的非 SLN 转移,这种术中工具可以帮助指导对乳腺癌患者进行 cALND 的决策。